"The first take-home message is that methylene blue is a good treatment for patients with bipolar disorder who have not stabilized on their current treatment," Dr. Alda said.
"The second message is that people with bipolar disorder can actually do quite well with treatment and can often improve to the point of full functioning. When we see patients who are quite a bit better, we should not be fully satisfied, and instead should aim for as complete a recovery as we can."
"The treatment is ideal for patients who do not improve 100% who are instead maybe at 70% to 80%, so they have stopped having depression and manic episodes but they are not quite there," he added. "These patients would be candidates for methylene blue. It's a 'fine-tuning' rather than a primary mood stabilizing treatment."
The study was funded by Stanley Medical Research Institute in Washington DC. Dr. Alda has disclosed no relevant financial relationships.
Has this study been posted already?
Edited by MorganM, 10 September 2011 - 05:01 PM.